SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($2.44), $0.70 better than the analyst estimate of ($3.14). Revenue for the quarter came in at $2.29 million versus the consensus estimate of $2.8 million.

“I want to take a moment to acknowledge the challenges resulting from the global COVID-19 pandemic. I’m proud of the way our employees, partners, and the community have responded in this unprecedented time,” said Jeff Jonas, M.D., chief executive officer at Sage Therapeutics. “The teams at Sage are handling virtual work well, and progress across our pipeline remains strong. Our mission is more important than ever as mental health issues are coming to the forefront and will continue to have significant impact even after the current phase of the COVID-19 pandemic is over. The strategic decisions we made in the first quarter, and the promotion of Mike to chief operating officer, have us on the right track, we believe, to continue developing medicines that matter for people with brain health disorders.”

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.